Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
THE AMERICAL JOURNAL OF PSYCHIATRY
Fecha de publicación: Marzo 2018
DOI: https://doi.org/10.1176/appi.ajp.2017.17040404
Autores: Claudia Bartels, Ph.D., Michael Wagner, Ph.D., Steffen Wolfsgruber, Ph.D., Hannelore Ehrenreich, M.D., Anja Schneider, M.D., for the Alzheimer’s Disease Neuroimaging Initiative
Background: Depression is associated with an increased risk of Alzheimer’s disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer’s dementia.
